autologous regulatory T cell-depleted lymphocytes

Autologous regulatory T cell-depleted lymphocytes is an investigational adoptive cell therapy consisting of a patient's own lymphocytes from which the immunosuppressive CD4+CD25+ regulatory T cell (Treg) population has been removed. Regulatory T cells typically function to maintain self-tolerance and suppress immune responses; however, in the context of malignancy, they can infiltrate tumors and inhibit the anti-tumor activity of effector T cells. By depleting these suppressive cells ex vivo, the remaining effector T cells, such as CD8+ cytotoxic T cells and CD4+ helper T cells, are intended to mount a more robust and sustained immune response against tumor cells upon re-infusion. This therapeutic approach is usually administered following a lymphodepleting conditioning regimen (e.g., cyclophosphamide and fludarabine) and is often supported by the administration of high-dose interleukin-2 (IL-2) to promote the expansion and persistence of the infused effector cells. The therapy was primarily developed and evaluated by the National Cancer Institute for the treatment of various refractory metastatic cancers.

Other names

autologous CD4+CD25+ regulatory T cell-depleted lymphocytesautologous Treg-depleted lymphocytesCD25-depleted autologous lymphocytesCD-25-depleted autologous lymphocytesCD 25-depleted autologous lymphocytesT-cell regulatory cell-depleted autologous lymphocytes